Can cannabinoids be a potential therapeutic tool in amyotrophic lateral sclerosis?

Sabrina Giacoppo, Emanuela Mazzon

Research output: Contribution to journalArticle

Abstract

Amyotrophic lateral sclerosis (ALS) is the most common degenerative disease of the motor neuron system. Over the last years, a growing interest was aimed to discovery new innovative and safer therapeutic approaches in the ALS treatment. In this context, the bioactive compounds of Cannabis sativa have shown antioxidant, anti-inflammatory and neuroprotective effects in preclinical models of central nervous system disease. However, most of the studies proving the ability of cannabinoids in delay disease progression and prolong survival in ALS were performed in animal model, whereas the few clinical trials that investigated cannabinoids-based medicines were focused only on the alleviation of ALS-related symptoms, not on the control of disease progression. The aim of this report was to provide a short but important overview of evidences that are useful to better characterize the efficacy as well as the molecular pathways modulated by cannabinoids.

Original languageEnglish
Pages (from-to)1896-1899
Number of pages4
JournalNeural Regeneration Research
Volume11
Issue number12
DOIs
Publication statusPublished - Dec 2016

Fingerprint

Cannabinoids
Amyotrophic Lateral Sclerosis
Motor Neuron Disease
Disease Progression
Central Nervous System Diseases
Neuroprotective Agents
Therapeutics
Cannabis
Anti-Inflammatory Agents
Animal Models
Antioxidants
Clinical Trials

Keywords

  • Journal Article
  • Review

Cite this

Can cannabinoids be a potential therapeutic tool in amyotrophic lateral sclerosis? / Giacoppo, Sabrina; Mazzon, Emanuela.

In: Neural Regeneration Research, Vol. 11, No. 12, 12.2016, p. 1896-1899.

Research output: Contribution to journalArticle

@article{4cc39eae8a584e24a11095c3ccb30089,
title = "Can cannabinoids be a potential therapeutic tool in amyotrophic lateral sclerosis?",
abstract = "Amyotrophic lateral sclerosis (ALS) is the most common degenerative disease of the motor neuron system. Over the last years, a growing interest was aimed to discovery new innovative and safer therapeutic approaches in the ALS treatment. In this context, the bioactive compounds of Cannabis sativa have shown antioxidant, anti-inflammatory and neuroprotective effects in preclinical models of central nervous system disease. However, most of the studies proving the ability of cannabinoids in delay disease progression and prolong survival in ALS were performed in animal model, whereas the few clinical trials that investigated cannabinoids-based medicines were focused only on the alleviation of ALS-related symptoms, not on the control of disease progression. The aim of this report was to provide a short but important overview of evidences that are useful to better characterize the efficacy as well as the molecular pathways modulated by cannabinoids.",
keywords = "Journal Article, Review",
author = "Sabrina Giacoppo and Emanuela Mazzon",
year = "2016",
month = "12",
doi = "10.4103/1673-5374.197125",
language = "English",
volume = "11",
pages = "1896--1899",
journal = "Neural Regeneration Research",
issn = "1673-5374",
publisher = "Editorial Board of Neural Regeneration Research",
number = "12",

}

TY - JOUR

T1 - Can cannabinoids be a potential therapeutic tool in amyotrophic lateral sclerosis?

AU - Giacoppo, Sabrina

AU - Mazzon, Emanuela

PY - 2016/12

Y1 - 2016/12

N2 - Amyotrophic lateral sclerosis (ALS) is the most common degenerative disease of the motor neuron system. Over the last years, a growing interest was aimed to discovery new innovative and safer therapeutic approaches in the ALS treatment. In this context, the bioactive compounds of Cannabis sativa have shown antioxidant, anti-inflammatory and neuroprotective effects in preclinical models of central nervous system disease. However, most of the studies proving the ability of cannabinoids in delay disease progression and prolong survival in ALS were performed in animal model, whereas the few clinical trials that investigated cannabinoids-based medicines were focused only on the alleviation of ALS-related symptoms, not on the control of disease progression. The aim of this report was to provide a short but important overview of evidences that are useful to better characterize the efficacy as well as the molecular pathways modulated by cannabinoids.

AB - Amyotrophic lateral sclerosis (ALS) is the most common degenerative disease of the motor neuron system. Over the last years, a growing interest was aimed to discovery new innovative and safer therapeutic approaches in the ALS treatment. In this context, the bioactive compounds of Cannabis sativa have shown antioxidant, anti-inflammatory and neuroprotective effects in preclinical models of central nervous system disease. However, most of the studies proving the ability of cannabinoids in delay disease progression and prolong survival in ALS were performed in animal model, whereas the few clinical trials that investigated cannabinoids-based medicines were focused only on the alleviation of ALS-related symptoms, not on the control of disease progression. The aim of this report was to provide a short but important overview of evidences that are useful to better characterize the efficacy as well as the molecular pathways modulated by cannabinoids.

KW - Journal Article

KW - Review

U2 - 10.4103/1673-5374.197125

DO - 10.4103/1673-5374.197125

M3 - Article

VL - 11

SP - 1896

EP - 1899

JO - Neural Regeneration Research

JF - Neural Regeneration Research

SN - 1673-5374

IS - 12

ER -